phosphorylcholine has been researched along with Recrudescence in 56 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The combination of lenalidomide-dexamethasone is active in multiple myeloma (MM)." | 9.16 | Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study. ( Alsina, M; Anderson, KC; Gardner, L; Giusti, K; Harvey, C; Hideshima, T; Jakubowiak, AJ; Kandarpa, M; Kaufman, JL; Kraftson, S; Poradosu, E; Richardson, PG; Ross, CW; Sportelli, P; Zimmerman, T, 2012) |
| "A prospective randomized double-blind controlled trial in children with recurrent acute otitis media and chronic otitis media with effusion; 240 children were randomized to receive a phosphorylcholine-coated tube in one ear and an uncoated tube in the other." | 9.15 | A randomized double-blind controlled trial of phosphorylcholine-coated tympanostomy tube versus standard tympanostomy tube in children with recurrent acute and chronic otitis media. ( Corsten, G; Hong, P; Johnson, LB; Smith, N, 2011) |
| " We aimed to assess the diagnostic accuracy of autoantibodies to apolipoprotein A-1 (anti-apoA-1 IgG) and to phosphorylcholine (anti-PC IgM) for non-ST segment elevation acute myocardial infarction (NSTEMI) and to explore their potential prognostic value." | 7.81 | Diagnostic and prognostic value of autoantibodies anti-apolipoprotein A-1 and anti-phosphorylcholine in acute non-ST elevation myocardial infarction. ( Grueter, D; Haaf, P; Jaeger, C; Montecucco, F; Mueller, C; Pagano, S; Reichlin, T; Rubini Gimenez, M; Twerenbold, R; Virzi, J; Vuilleumier, N; Wildi, K, 2015) |
| " One hundred and fifty patients aged ≥18 years with serologically confirmed HIV and parasitologically confirmed VL were randomly allocated to 1 of 2 treatment arms, either a total 40 mg/kg intravenous liposomal amphotericin B (AmBisome; Gilead Pharmaceuticals) administered in 8 equal doses over 24 days or a total 30 mg/kg intravenous AmBisome administered in 6 equal doses given concomitantly with a total 1." | 5.51 | AmBisome Monotherapy and Combination AmBisome-Miltefosine Therapy for the Treatment of Visceral Leishmaniasis in Patients Coinfected With Human Immunodeficiency Virus in India: A Randomized Open-Label, Parallel-Arm, Phase 3 Trial. ( Alexander, N; Alves, F; Burza, S; Das, P; Das, VNR; de Lima Pereira, A; Gill, N; Goyal, V; Harshana, A; Kazmi, S; Kumar, D; Kumar, V; Lal, CS; Lasry, E; Mahajan, R; Pandey, K; Rewari, B; Rijal, S; Verma, N, 2022) |
| "Visceral leishmaniasis is an opportunistic infection that affects human immunodeficiency virus-infected persons in leishmaniasis-endemic areas." | 5.36 | Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient. ( Barragán, P; López-Velez, R; Olmo, M; Podzamczer, D, 2010) |
| "Embedded in a clinical trial in Northwest Ethiopia, RNA-Seq was performed on whole blood samples of 28 VL-HIV patients before and after completion of a 29-day treatment regimen of AmBisome or AmBisome/miltefosine." | 5.34 | Host transcriptomic signature as alternative test-of-cure in visceral leishmaniasis patients co-infected with HIV. ( Adriaensen, W; Alves, F; Blesson, S; Cnops, L; Cordero, CF; Cuypers, B; Diro, E; Kaye, PM; Mengasha, B; van Griensven, J, 2020) |
| "The combination of lenalidomide-dexamethasone is active in multiple myeloma (MM)." | 5.16 | Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study. ( Alsina, M; Anderson, KC; Gardner, L; Giusti, K; Harvey, C; Hideshima, T; Jakubowiak, AJ; Kandarpa, M; Kaufman, JL; Kraftson, S; Poradosu, E; Richardson, PG; Ross, CW; Sportelli, P; Zimmerman, T, 2012) |
| "A prospective randomized double-blind controlled trial in children with recurrent acute otitis media and chronic otitis media with effusion; 240 children were randomized to receive a phosphorylcholine-coated tube in one ear and an uncoated tube in the other." | 5.15 | A randomized double-blind controlled trial of phosphorylcholine-coated tympanostomy tube versus standard tympanostomy tube in children with recurrent acute and chronic otitis media. ( Corsten, G; Hong, P; Johnson, LB; Smith, N, 2011) |
| " We aimed to assess the diagnostic accuracy of autoantibodies to apolipoprotein A-1 (anti-apoA-1 IgG) and to phosphorylcholine (anti-PC IgM) for non-ST segment elevation acute myocardial infarction (NSTEMI) and to explore their potential prognostic value." | 3.81 | Diagnostic and prognostic value of autoantibodies anti-apolipoprotein A-1 and anti-phosphorylcholine in acute non-ST elevation myocardial infarction. ( Grueter, D; Haaf, P; Jaeger, C; Montecucco, F; Mueller, C; Pagano, S; Reichlin, T; Rubini Gimenez, M; Twerenbold, R; Virzi, J; Vuilleumier, N; Wildi, K, 2015) |
| " Combination regimens including AmBisome, paromomycin and miltefosine have proved to be safe and effective in the treatment of VL in India." | 2.84 | Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh. ( Alvar, J; Alves, F; Balasegaram, M; Boer, MD; Ellis, S; Faiz, A; Goyal, V; Haque, R; Jamil, K; Rahman, R; Rijal, S; Samad, R; Sharma, B; Strub-Wourgaft, N, 2017) |
| "Low efficacy of miltefosine in the treatment of visceral leishmaniasis was recently observed in Eastern Africa." | 2.84 | Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study. ( Alves, F; Balasegaram, M; Beijnen, JH; Dorlo, TPC; Ellis, SJ; Hailu, A; Karlsson, MO; Khalil, EAG; Kip, AE; Kirigi, G; Musa, AM; Njenga, S; Olobo, J; Wasunna, M; Younis, BM, 2017) |
| " The adverse effects were primarily gastrointestinal for miltefosine and pain at the lesion site after treatment for thermotherapy." | 2.78 | Thermotherapy effective and safer than miltefosine in the treatment of cutaneous leishmaniasis in Colombia. ( Cruz, C; Godoy, G; López, L; Robledo, SM; Vélez, ID, 2013) |
| "Combination treatments for visceral leishmaniasis are efficacious and safe, and decrease the duration of therapy, thereby encouraging adherence and reducing emergence of drug-resistant parasites." | 2.76 | Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. ( Alam, S; Arora, R; Balasegaram, M; Chakravarty, J; Das, P; Ellis, S; Kumari, P; Lal, CS; Modabber, F; Nawin, K; Olliaro, P; Pandey, K; Rai, M; Sharma, B; Sinha, PK; Strub-Wourgaft, N; Sundar, S; Vaillant, M; Verma, DK; Verma, N, 2011) |
| "Waldenström's macroglobulinemia (WM) is a rare, low-grade lymphoproliferative disorder." | 2.75 | Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. ( Anderson, KC; Azab, AK; Azab, F; Chuma, S; Ghobrial, IM; Harris, B; Hong, F; Jia, X; Leduc, R; Leleu, X; Richardson, PG; Roccaro, A; Rodig, S; Rourke, M; Rubin, N; Sacco, A; Sportelli, P; Varticovski, L; Warren, D; Weller, E, 2010) |
| "Miltefosine is an oral agent that has been shown in small numbers of patients to have a favorable therapeutic index for Indian visceral leishmaniasis." | 2.70 | Oral miltefosine for Indian visceral leishmaniasis. ( Berman, J; Bryceson, A; Engel, J; Fischer, C; Jha, TK; Junge, K; Sindermann, H; Sundar, S; Thakur, CP, 2002) |
| "Miltefosine is a phosphocholine analogue that affects cell-signaling pathways and membrane synthesis." | 2.69 | Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. ( Bachmann, P; Berman, J; Fischer, C; Jha, TK; Karbwang, J; Sundar, S; Thakur, CP; Voss, A, 1999) |
| "Frequent relapses are observed in co-infected HIV who can benefit of a second cycle." | 2.55 | Visceral leishmaniosis in immunocompromised host: an update and literature review. ( Esposito, S; Pagliano, P, 2017) |
| "Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment." | 2.50 | New approaches to management of multiple myeloma. ( Cavallo, F; Genadieva-Stavric, S; Palumbo, A, 2014) |
| "After 5 years the probability of recurrence in patients with PC-IgM levels in the highest tertile (> 19." | 1.48 | Natural antibodies to oxidation-specific epitopes: innate immune response and venous thromboembolic disease. ( Binder, CJ; Eichinger, S; Eischer, L; Kammer, M; Kyrle, PA; Ozsvar Kozma, M, 2018) |
| " A VLPV expert committee and a UHC VLPV team were established, an operational manual and pharmacovigilance report forms were developed, training and refresher training of health personnel took place at UHCs and at the central level, collected information such as patient data including demographics, treatment history and response, adverse events were analyzed." | 1.48 | Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme. ( Ahuja, V; Ghosh, P; Haque, R; Hossain, AFMA; Hossain, MA; Hossain, MS; Kumar, A; Mahshin, M; Maruf, S; Mondal, D; Shamsuzzaman, AKM; Sharma, A; Sharma, V, 2018) |
| "Miltefosine (MIL) is an oral antileishmanial drug used for treatment of visceral leishmaniasis (VL) in the Indian subcontinent." | 1.46 | Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stress. ( Bhandari, V; Deep, DK; Dujardin, JC; Ramesh, V; Salotra, P; Sharma, V; Singh, R; Sundar, S; Verma, A; Wajid, S, 2017) |
| "Treatments by miltefosine, amphotericin B, N-methyl-glucamine antimoniate were subsequently initiated." | 1.46 | Recurrence of visceral and muco-cutaneous leishmaniasis in a patient under immunosuppressive therapy. ( Arrese Estrada, J; Cnops, L; Darcis, G; de Leval, L; Giot, JB; Hayette, MP; Leonard, P; Moutschen, M; Tassin, F; Van der Auwera, G, 2017) |
| "Cure/relapse was ascertained by clinical and histopathological examination, and measuring parasite burden by quantitative real-time PCR." | 1.42 | Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India. ( Avishek, K; Deep, DK; Ramesh, V; Salotra, P; Singh, R; Verma, A; Verma, S, 2015) |
| "Relapse was 2 times more common amongst male patients (IRR 2." | 1.40 | Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia. ( Boelaert, M; Dorlo, TP; Dujardin, JC; Hasker, E; Ostyn, B; Rijal, S; Sundar, S, 2014) |
| "Parasite fingerprints of pretreatment and relapse bone marrow isolates within 8 patients were similar, suggesting that clinical relapses were not due to reinfection with a new strain." | 1.39 | Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. ( Beijnen, JH; Bhattarai, NR; Boelaert, M; Das, ML; Decuypere, S; Dhakal, SS; Dorlo, TP; Dujardin, JC; Karki, P; Ostyn, B; Rai, K; Rijal, S; Singh, R; Uranw, S; Vanaerschot, M, 2013) |
| "The third relapse was treated with oral miltefosine with complete resolution of the lesions." | 1.39 | Treatment of mucosal leishmaniasis (L. infantum) with miltefosine in a patient with Good syndrome. ( Arnold, A; Blum, J; Holbro, A; Neumayr, A; Stoeckle, M; Weisser, M, 2013) |
| "Visceral leishmaniasis is an opportunistic infection that affects human immunodeficiency virus-infected persons in leishmaniasis-endemic areas." | 1.36 | Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient. ( Barragán, P; López-Velez, R; Olmo, M; Podzamczer, D, 2010) |
| "Miltefosine is a less toxic option to replace the antimony compounds." | 1.34 | [Cutaneous leishmaniasis]. ( Sunderkötter, C; von Stebut, E, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (7.14) | 18.2507 |
| 2000's | 11 (19.64) | 29.6817 |
| 2010's | 35 (62.50) | 24.3611 |
| 2020's | 6 (10.71) | 2.80 |
| Authors | Studies |
|---|---|
| Burza, S | 5 |
| Mahajan, R | 3 |
| Kazmi, S | 1 |
| Alexander, N | 1 |
| Kumar, D | 3 |
| Kumar, V | 1 |
| Lasry, E | 1 |
| Harshana, A | 1 |
| de Lima Pereira, A | 1 |
| Das, P | 5 |
| Verma, N | 3 |
| Das, VNR | 2 |
| Lal, CS | 3 |
| Rewari, B | 1 |
| Goyal, V | 3 |
| Rijal, S | 7 |
| Alves, F | 5 |
| Gill, N | 1 |
| Pandey, K | 6 |
| Mano, C | 1 |
| Kongkaew, A | 1 |
| Tippawangkosol, P | 1 |
| Junkum, A | 1 |
| Siriyasatien, P | 1 |
| Jariyapan, N | 1 |
| Singh, SN | 1 |
| Singh, RS | 1 |
| Strub-Wourgaft, N | 3 |
| Bern, C | 1 |
| Hightower, A | 1 |
| Sunyoto, T | 2 |
| Lima, N | 1 |
| Alvar, J | 2 |
| Ramesh, V | 3 |
| Dixit, KK | 1 |
| Sharma, N | 1 |
| Singh, R | 4 |
| Salotra, P | 3 |
| Camilleri, M | 1 |
| Richards, H | 1 |
| Pomplun, S | 1 |
| Wilson, A | 1 |
| Checkley, A | 1 |
| Rabin, N | 1 |
| Adriaensen, W | 1 |
| Cuypers, B | 2 |
| Cordero, CF | 1 |
| Mengasha, B | 1 |
| Blesson, S | 1 |
| Cnops, L | 2 |
| Kaye, PM | 1 |
| Diro, E | 1 |
| van Griensven, J | 1 |
| Jaiteh, MB | 1 |
| İnkaya, AÇ | 1 |
| Üner, A | 1 |
| Elçin, G | 1 |
| Ergüven, S | 1 |
| Kurtulan, O | 1 |
| Harxhi, A | 1 |
| Akova, M | 1 |
| Pagliano, P | 1 |
| Esposito, S | 1 |
| Rahman, R | 1 |
| Haque, R | 2 |
| Jamil, K | 1 |
| Faiz, A | 1 |
| Samad, R | 1 |
| Ellis, S | 2 |
| Balasegaram, M | 3 |
| Boer, MD | 1 |
| Sharma, B | 2 |
| Deep, DK | 2 |
| Bhandari, V | 1 |
| Verma, A | 2 |
| Sharma, V | 2 |
| Wajid, S | 1 |
| Sundar, S | 7 |
| Dujardin, JC | 6 |
| Darcis, G | 1 |
| Van der Auwera, G | 1 |
| Giot, JB | 1 |
| Hayette, MP | 1 |
| Tassin, F | 1 |
| Arrese Estrada, J | 1 |
| Moutschen, M | 1 |
| de Leval, L | 1 |
| Leonard, P | 1 |
| Dorlo, TPC | 1 |
| Kip, AE | 1 |
| Younis, BM | 1 |
| Ellis, SJ | 1 |
| Beijnen, JH | 2 |
| Njenga, S | 1 |
| Kirigi, G | 1 |
| Hailu, A | 1 |
| Olobo, J | 1 |
| Musa, AM | 1 |
| Wasunna, M | 1 |
| Karlsson, MO | 1 |
| Khalil, EAG | 1 |
| Eichinger, S | 1 |
| Kyrle, PA | 1 |
| Kammer, M | 1 |
| Eischer, L | 1 |
| Ozsvar Kozma, M | 1 |
| Binder, CJ | 1 |
| Tiwary, P | 1 |
| Hossain, MS | 1 |
| Kumar, A | 1 |
| Hossain, AFMA | 1 |
| Mahshin, M | 1 |
| Sharma, A | 1 |
| Hossain, MA | 1 |
| Shamsuzzaman, AKM | 1 |
| Maruf, S | 1 |
| Ghosh, P | 1 |
| Ahuja, V | 1 |
| Mondal, D | 1 |
| Hendrickx, S | 3 |
| Bulté, D | 1 |
| Van den Kerkhof, M | 1 |
| Cos, P | 2 |
| Delputte, P | 2 |
| Maes, L | 3 |
| Caljon, G | 2 |
| Ostyn, B | 3 |
| Uranw, S | 2 |
| Rai, K | 2 |
| Bhattarai, NR | 3 |
| Dorlo, TP | 2 |
| Vanaerschot, M | 3 |
| Decuypere, S | 1 |
| Dhakal, SS | 1 |
| Das, ML | 1 |
| Karki, P | 1 |
| Boelaert, M | 3 |
| López, L | 1 |
| Cruz, C | 1 |
| Godoy, G | 1 |
| Robledo, SM | 1 |
| Vélez, ID | 1 |
| Stoeckle, M | 1 |
| Holbro, A | 1 |
| Arnold, A | 1 |
| Neumayr, A | 1 |
| Weisser, M | 1 |
| Blum, J | 1 |
| Nabi, E | 1 |
| Mitra, G | 2 |
| Lima, MA | 2 |
| Berg, M | 1 |
| Genadieva-Stavric, S | 1 |
| Cavallo, F | 1 |
| Palumbo, A | 1 |
| Dumetz, F | 1 |
| Roy, S | 2 |
| Ponte-Sucre, A | 1 |
| Arevalo, J | 1 |
| Patole, S | 1 |
| Varghese, GM | 1 |
| Hasker, E | 1 |
| Guidetti, A | 1 |
| Carlo-Stella, C | 1 |
| Locatelli, SL | 1 |
| Malorni, W | 1 |
| Mortarini, R | 1 |
| Viviani, S | 1 |
| Russo, D | 1 |
| Marchianò, A | 1 |
| Sorasio, R | 1 |
| Dodero, A | 1 |
| Farina, L | 1 |
| Giordano, L | 1 |
| Di Nicola, M | 1 |
| Anichini, A | 1 |
| Corradini, P | 1 |
| Gianni, AM | 1 |
| Rubini Gimenez, M | 1 |
| Pagano, S | 1 |
| Virzi, J | 1 |
| Montecucco, F | 1 |
| Twerenbold, R | 1 |
| Reichlin, T | 1 |
| Wildi, K | 1 |
| Grueter, D | 1 |
| Jaeger, C | 1 |
| Haaf, P | 1 |
| Vuilleumier, N | 1 |
| Mueller, C | 1 |
| Isaakidis, P | 1 |
| Sagili, KD | 1 |
| Van Geertruyden, JP | 1 |
| Ghosh, S | 1 |
| Das, NK | 1 |
| Mukherjee, S | 1 |
| Mukhopadhyay, D | 1 |
| Barbhuiya, JN | 1 |
| Hazra, A | 1 |
| Chatterjee, M | 2 |
| Eberhardt, E | 1 |
| Mondelaers, A | 1 |
| Ganguly, S | 1 |
| Saha, P | 1 |
| Ghosh, TK | 1 |
| Guha, SK | 1 |
| Kundu, PK | 1 |
| Bera, DK | 1 |
| Basu, N | 1 |
| Maji, AK | 1 |
| Avishek, K | 1 |
| Verma, S | 1 |
| Guerin, PJ | 1 |
| Croft, SL | 1 |
| Manna, L | 1 |
| Vitale, F | 1 |
| Reale, S | 1 |
| Picillo, E | 1 |
| Neglia, G | 1 |
| Vescio, F | 1 |
| Gravino, AE | 1 |
| Pandey, BD | 1 |
| Kaneko, O | 1 |
| Yanagi, T | 1 |
| Hirayama, K | 1 |
| Ghobrial, IM | 2 |
| Roccaro, A | 1 |
| Hong, F | 1 |
| Weller, E | 1 |
| Rubin, N | 1 |
| Leduc, R | 1 |
| Rourke, M | 1 |
| Chuma, S | 1 |
| Sacco, A | 1 |
| Jia, X | 1 |
| Azab, F | 1 |
| Azab, AK | 1 |
| Rodig, S | 1 |
| Warren, D | 1 |
| Harris, B | 1 |
| Varticovski, L | 1 |
| Sportelli, P | 3 |
| Leleu, X | 1 |
| Anderson, KC | 3 |
| Richardson, PG | 3 |
| Barragán, P | 1 |
| López-Velez, R | 1 |
| Olmo, M | 1 |
| Podzamczer, D | 1 |
| Hong, P | 1 |
| Smith, N | 1 |
| Johnson, LB | 1 |
| Corsten, G | 1 |
| Sinha, PK | 2 |
| Rai, M | 1 |
| Verma, DK | 1 |
| Nawin, K | 1 |
| Alam, S | 1 |
| Chakravarty, J | 1 |
| Vaillant, M | 1 |
| Kumari, P | 1 |
| Arora, R | 1 |
| Olliaro, P | 1 |
| Modabber, F | 1 |
| Kumar, N | 1 |
| Ranjan, A | 1 |
| Verma, RB | 1 |
| Wolf, J | 1 |
| Jakubowiak, A | 1 |
| Zonder, J | 1 |
| Lonial, S | 1 |
| Irwin, D | 1 |
| Densmore, J | 1 |
| Krishnan, A | 1 |
| Raje, N | 1 |
| Bar, M | 1 |
| Martin, T | 1 |
| Schlossman, R | 1 |
| Munshi, N | 1 |
| Laubach, J | 1 |
| Allerton, J | 1 |
| Hideshima, T | 2 |
| Colson, K | 1 |
| Poradosu, E | 2 |
| Gardner, L | 2 |
| Cojean, S | 1 |
| Houzé, S | 1 |
| Haouchine, D | 1 |
| Huteau, F | 1 |
| Lariven, S | 1 |
| Hubert, V | 1 |
| Michard, F | 1 |
| Bories, C | 1 |
| Pratlong, F | 2 |
| Le Bras, J | 1 |
| Loiseau, PM | 1 |
| Matheron, S | 1 |
| Jakubowiak, AJ | 1 |
| Zimmerman, T | 1 |
| Alsina, M | 1 |
| Kaufman, JL | 1 |
| Kandarpa, M | 1 |
| Kraftson, S | 1 |
| Ross, CW | 1 |
| Harvey, C | 1 |
| Giusti, K | 1 |
| Swanson, N | 1 |
| Javed, Q | 1 |
| Hogrefe, K | 1 |
| Gershlick, A | 1 |
| Jha, TK | 2 |
| Thakur, CP | 2 |
| Engel, J | 1 |
| Sindermann, H | 3 |
| Fischer, C | 2 |
| Junge, K | 1 |
| Bryceson, A | 1 |
| Berman, J | 2 |
| Bommer, W | 1 |
| Eibl, HJ | 1 |
| Engel, KR | 1 |
| Kuhlencord, A | 1 |
| Zappel, H | 1 |
| Rihl, M | 1 |
| Stoll, M | 1 |
| Ulbricht, K | 1 |
| Bange, FC | 1 |
| Schmidt, RE | 1 |
| Calvopina, M | 1 |
| Gomez, EA | 1 |
| Cooper, PJ | 1 |
| Hashiguchi, Y | 1 |
| Iqbal, J | 1 |
| Bukhari, I | 1 |
| Jamshid, M | 1 |
| Bashir, S | 1 |
| Masoom Yasinzai, M | 1 |
| Anwar, M | 1 |
| Zerpa, O | 1 |
| Ulrich, M | 1 |
| Blanco, B | 1 |
| Polegre, M | 1 |
| Avila, A | 1 |
| Matos, N | 1 |
| Mendoza, I | 1 |
| Ravel, C | 1 |
| Convit, J | 1 |
| von Stebut, E | 1 |
| Sunderkötter, C | 1 |
| Wysluch, A | 1 |
| Sommerer, F | 1 |
| Ramadan, H | 1 |
| Loeffelbein, D | 1 |
| Wolff, KD | 1 |
| Hölzle, F | 1 |
| Ekdahl, K | 1 |
| Braconier, JH | 1 |
| Svanborg, C | 1 |
| Bachmann, P | 1 |
| Karbwang, J | 1 |
| Voss, A | 1 |
| Phibbs, RH | 1 |
| Ballard, RA | 1 |
| Clements, JA | 1 |
| Heilbron, DC | 1 |
| Phibbs, CS | 1 |
| Schlueter, MA | 1 |
| Sniderman, SH | 1 |
| Tooley, WH | 1 |
| Wakeley, A | 1 |
| Jørgensen, F | 1 |
| Andersson, B | 1 |
| Hanson, LA | 1 |
| Nylén, O | 1 |
| Edén, CS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III, Open Label, Randomised, Study of Three Short Course Combination Regimens (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome® Alone for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh[NCT01122771] | Phase 3 | 602 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
| Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia.[NCT00471705] | Phase 3 | 437 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia[NCT00398710] | Phase 2 | 37 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia[NCT00422656] | Phase 2 | 37 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Randomized, Open-label, Parallel-group, Safety & Efficacy Study to Evaluate Different Combination Treatment Regimens, of Either AmBisome and Paromomycin, AmBisome and Miltefosine, or Paromomycin and Miltefosine Compared With Amphotericin B Deoxycholate (t[NCT00696969] | Phase 3 | 634 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| An Open-Label Phase I/II Study of the Safety and Efficacy of Perifosine and Bortezomib With or Without Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Bortezomib[NCT00401011] | Phase 1/Phase 2 | 84 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| An Open-Label Phase I Study of the Safety of Perifosine in Combination With Lenalidomide and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma[NCT00415064] | Phase 1 | 32 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Complete Clinical response: Initial cure plus the absence of recurrences or mucosal lesions for 6 months after the end of treatment.~Note: nitial cure: Complete re-epithelialization of all ulcers and complete disappearance of the induration up to 3 months after the end of treatment." (NCT00471705)
Timeframe: Until 6 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 85 |
| Glucantime® | 103 |
| Thermotherapy | 86 |
At least 50% increase in lesion size at the end of treatment, absence of clinical response at 6 weeks, or any sign of lesion activity 3 months after the end of treatment (NCT00471705)
Timeframe: Until 3 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 34 |
| Glucantime® | 14 |
| Thermotherapy | 42 |
Reactivation of the lesion at the original site after cure or mucosal compromise during follow-up. (NCT00471705)
Timeframe: Until 6 months post-treatment
| Intervention | Participants (Number) |
|---|---|
| Miltefosine | 3 |
| Glucantime® | 4 |
| Thermotherapy | 6 |
OR rate is the percentage of patients achieving Complete Response (CR), Partial Response (PR) or Minimal Response (MR) during treatment based on criteria from the 2nd International Workshop on WM. (Weber D, Treon S, et al. Seminars in Oncology 2003). CR: Disappearance of serum monoclonal IgM protein (IgM M-protein) by immunofixation; no histologic evidence of bone marrow (BM) involvement, resolution of any adenopathy/organomegaly (confirmed by CT scan); PR: At least 50% reduction of IgM M-protein and at least 50% decrease in adenopathy/organomegaly on physical examination or on CT scan; and MR: At least 25% but less than 50% reduction of IgM M-protein by protein electrophoresis. Patients must have no new symptoms or signs of active disease. (NCT00422656)
Timeframe: Disease was assessed every cycle for the first 12 months and every 3 months thereafter. The median duration of treatment with perifosine was 5.6 months (range, 1.8- 21.5+).
| Intervention | percentage of patients (Number) |
|---|---|
| Perifosine | 38 |
PFS estimated using the Kaplan-Meier method is defined as the time from registration to death from any cause or disease progression (PD) based on criteria from the 2nd International Workshop on WM. (Weber D, Treon S, et al. Seminars in Oncology 2003) Patients alive without PD are censored at time of last disease assessment. PD: At least 25% increase in serum monoclonal IgM protein by electrophoresis confirmed with a second measurement at least 2 weeks apart, or progression of clinically significant findings due to disease (i.e., anemia, thrombocytopenia, leucopenia, bulky adenopathy/organomegaly) or symptoms (unexplained recurrent fever of at least 38.4oC, drenching night sweats, at least 10% body weight less, or hyperviscosity, neuropathy, symptomatic cryoglobulinemia, or amyloidosis) attributable to WM. (NCT00422656)
Timeframe: Disease was assessed every cycle for the first 12 months and every 3 months thereafter. Median follow-up time was 19.5 months and range up to 24 months.
| Intervention | months (Median) |
|---|---|
| Perifosine | 12.6 |
TTP estimated using the Kaplan-Meier method is defined as the time from registration to disease progression (PD) based on criteria from the 2nd International Workshop on WM. (Weber D, Treon S, et al. Seminars in Oncology 2003) Patients without PD are censored at time of last disease assessment. PD: At least 25% increase in serum monoclonal IgM protein by electrophoresis confirmed with a second measurement at least 2 weeks apart, or progression of clinically significant findings due to disease (i.e., anemia, thrombocytopenia, leucopenia, bulky adenopathy/organomegaly) or symptoms (unexplained recurrent fever of at least 38.4oC, drenching night sweats, at least 10% body weight less, or hyperviscosity, neuropathy, symptomatic cryoglobulinemia, or amyloidosis) attributable to WM. (NCT00422656)
Timeframe: Disease was assessed every cycle for the first 12 months and every 3 months thereafter. Median follow-up time was 19.5 months and range up to 24 months.
| Intervention | months (Median) |
|---|---|
| Perifosine | 12.6 |
The percentage of patients experiencing treatment-related grade 3-4 adverse events based on CTCAEv3 as reported on case report forms. (NCT00422656)
Timeframe: Adverse events were collected every cycle on treatment.The median treatment duration was 5.6 months (range, 1.8-21.5+).
| Intervention | percentage of patients (Number) |
|---|---|
| Perifosine | 35 |
5 reviews available for phosphorylcholine and Recrudescence
| Article | Year |
|---|---|
Visceral leishmaniosis in immunocompromised host: an update and literature review.
Topics: Amphotericin B; HIV Infections; Humans; Immunocompromised Host; Leishmaniasis, Visceral; Phosphorylc | 2017 |
New approaches to management of multiple myeloma.
Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Boron Compounds; Boronic Ac | 2014 |
Treatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype?
Topics: Animals; Antiprotozoal Agents; Drug Resistance; Humans; Insect Vectors; Leishmania; Leishmaniasis; P | 2014 |
Evaluating drug resistance in visceral leishmaniasis: the challenges.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Resistance, Multiple; Humans; Leishmania donovan | 2018 |
[The leishmaniasis - a parasitel infection as differential diagnosis of malignant tumours of oral mucosa. A case report and review of literature].
Topics: Animals; Combined Modality Therapy; Diagnosis, Differential; Hepatitis C, Chronic; Histiocytes; Huma | 2007 |
16 trials available for phosphorylcholine and Recrudescence
| Article | Year |
|---|---|
AmBisome Monotherapy and Combination AmBisome-Miltefosine Therapy for the Treatment of Visceral Leishmaniasis in Patients Coinfected With Human Immunodeficiency Virus in India: A Randomized Open-Label, Parallel-Arm, Phase 3 Trial.
Topics: Adolescent; Adult; Amphotericin B; Antiprotozoal Agents; Coinfection; Drug Therapy, Combination; HIV | 2022 |
Host transcriptomic signature as alternative test-of-cure in visceral leishmaniasis patients co-infected with HIV.
Topics: Adult; Amphotericin B; Antiprotozoal Agents; Coinfection; Endoribonucleases; Female; Gene Expression | 2020 |
Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
Topics: Adolescent; Adult; Amphotericin B; Antiprotozoal Agents; Bangladesh; Child; Child, Preschool; Drug T | 2017 |
Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study.
Topics: Adolescent; Adult; Africa, Eastern; Antiprotozoal Agents; Biological Availability; Child; Female; Hu | 2017 |
Thermotherapy effective and safer than miltefosine in the treatment of cutaneous leishmaniasis in Colombia.
Topics: Adult; Antiprotozoal Agents; Colombia; Follow-Up Studies; Humans; Hyperthermia, Induced; Leishmanias | 2013 |
Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Extracellular S | 2014 |
Inadequacy of 12-Week Miltefosine Treatment for Indian Post-Kala-Azar Dermal Leishmaniasis.
Topics: Adolescent; Adult; Antiprotozoal Agents; Child; Drug Administration Schedule; Female; Humans; Leishm | 2015 |
Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Male; Middle Aged; Oligopepti | 2010 |
Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Male; Middle Aged; Oligopepti | 2010 |
Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Male; Middle Aged; Oligopepti | 2010 |
Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Male; Middle Aged; Oligopepti | 2010 |
A randomized double-blind controlled trial of phosphorylcholine-coated tympanostomy tube versus standard tympanostomy tube in children with recurrent acute and chronic otitis media.
Topics: Acute Disease; Child; Child, Preschool; Chronic Disease; Coated Materials, Biocompatible; Double-Bli | 2011 |
Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
Topics: Adolescent; Adult; Amphotericin B; Antiprotozoal Agents; Child; Child, Preschool; Creatinine; Dose-R | 2011 |
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2011 |
Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationsh | 2012 |
Oral miltefosine for Indian visceral leishmaniasis.
Topics: Administration, Oral; Adolescent; Adult; Amphotericin B; Animals; Antiprotozoal Agents; Female; Huma | 2002 |
Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis.
Topics: Administration, Oral; Adolescent; Adult; Antiprotozoal Agents; Aspartate Aminotransferases; Female; | 1999 |
Initial clinical trial of EXOSURF, a protein-free synthetic surfactant, for the prophylaxis and early treatment of hyaline membrane disease.
Topics: Administration, Inhalation; Birth Weight; Drug Combinations; Drug Evaluation; Fatty Alcohols; Follow | 1991 |
Gamma-globulin treatment of recurrent acute otitis media in children.
Topics: Acute Disease; Female; Follow-Up Studies; Humans; Immunization, Passive; Immunoglobulin A, Secretory | 1990 |
35 other studies available for phosphorylcholine and Recrudescence
| Article | Year |
|---|---|
In vitro susceptibility to miltefosine of amphotericin B-resistant Leishmania (Mundinia) martiniquensis.
Topics: Amphotericin B; Antiprotozoal Agents; Chronic Disease; Humans; Leishmania; Leishmaniasis; Leishmania | 2023 |
Field effectiveness of new visceral leishmaniasis regimens after 1 year following treatment within public health facilities in Bihar, India.
Topics: Adolescent; Amphotericin B; Antiprotozoal Agents; Child; Child, Preschool; Cohort Studies; Drug Ther | 2019 |
Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis.
Topics: Adolescent; Adult; Amphotericin B; Antiprotozoal Agents; Child; DNA, Protozoan; Drug Therapy, Combin | 2020 |
Leishmaniasis as an unusual cause of pancytopenia in a patient receiving immunomodulatory therapy for myeloma.
Topics: Aged; Antiprotozoal Agents; Combined Modality Therapy; Drug Substitution; Endemic Diseases; Humans; | 2020 |
Persistent dermal lesions in a patient with previous history of visceral leishmaniasis.
Topics: Albania; Amphotericin B; Antiprotozoal Agents; Fatal Outcome; Humans; Leishmania infantum; Leishmani | 2021 |
Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stress.
Topics: Animals; Antiprotozoal Agents; Drug Resistance; Fluorometry; Humans; Leishmania donovani; Leishmania | 2017 |
Recurrence of visceral and muco-cutaneous leishmaniasis in a patient under immunosuppressive therapy.
Topics: Amphotericin B; Antiprotozoal Agents; Biopsy; Female; Humans; Immunocompromised Host; Leishmania; Le | 2017 |
Natural antibodies to oxidation-specific epitopes: innate immune response and venous thromboembolic disease.
Topics: Adult; Autoantibodies; Biomarkers; Blood Coagulation; Epitopes; Female; Humans; Immunity, Innate; Im | 2018 |
Identification and Functional Validation of a Biomarker for the Diagnosis of Miltefosine Relapse during Visceral Leishmaniasis.
Topics: Antiprotozoal Agents; Biomarkers; Biopsy, Needle; Calpain; Humans; Leishmania donovani; Leishmaniasi | 2018 |
Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Amphotericin B; Antiprotozoal Agents; Bangladesh; Fema | 2018 |
Immunosuppression of Syrian golden hamsters accelerates relapse but not the emergence of resistance in Leishmania infantum following recurrent miltefosine pressure.
Topics: Animals; Antiprotozoal Agents; CD4-Positive T-Lymphocytes; Cricetinae; Cyclophosphamide; Drug Resist | 2019 |
Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance.
Topics: Adolescent; Adult; Antiprotozoal Agents; Child; Child, Preschool; Drug Resistance; Female; Humans; K | 2013 |
Treatment of mucosal leishmaniasis (L. infantum) with miltefosine in a patient with Good syndrome.
Topics: Administration, Oral; Aged; Antiprotozoal Agents; Histocytochemistry; Humans; Immunocompromised Host | 2013 |
One-year follow-up of immunocompetent male patients treated with miltefosine for primary visceral leishmaniasis in Bihar, India.
Topics: Antiprotozoal Agents; Child; Follow-Up Studies; Humans; India; Leishmaniasis, Visceral; Male; Phosph | 2013 |
Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain.
Topics: Antiprotozoal Agents; Humans; Leishmania donovani; Leishmaniasis, Visceral; Phosphorylcholine; Recur | 2013 |
Multiple relapses of visceral leishmaniasis in a patient with HIV in India: a treatment challenge.
Topics: Adult; Amphotericin B; Antiprotozoal Agents; Antiretroviral Therapy, Highly Active; Coinfection; HIV | 2014 |
Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia.
Topics: Adolescent; Adult; Age Factors; Antiprotozoal Agents; Child; Child, Preschool; Female; Humans; India | 2014 |
Diagnostic and prognostic value of autoantibodies anti-apolipoprotein A-1 and anti-phosphorylcholine in acute non-ST elevation myocardial infarction.
Topics: Aged; Aged, 80 and over; Apolipoprotein A-I; Area Under Curve; Autoantibodies; Case-Control Studies; | 2015 |
Combination Treatment for Visceral Leishmaniasis Patients Coinfected with Human Immunodeficiency Virus in India.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Amphotericin B; Coinfection; D | 2015 |
Lack of correlation between the promastigote back-transformation assay and miltefosine treatment outcome.
Topics: Antiprotozoal Agents; Drug Resistance; Humans; Leishmania donovani; Leishmaniasis, Visceral; Nepal; | 2015 |
PKDL--A Silent Parasite Pool for Transmission of Leishmaniasis in Kala-azar Endemic Areas of Malda District, West Bengal, India.
Topics: Administration, Oral; Adolescent; Adult; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; C | 2015 |
Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India.
Topics: Adult; Antiprotozoal Agents; Child; Female; Histocytochemistry; Humans; India; Leishmaniasis, Cutane | 2015 |
Study of efficacy of miltefosine and allopurinol in dogs with leishmaniosis.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Disease Models, Animal; Disease Reservoirs; Dog Diseases | 2009 |
Relapse of visceral leishmaniasis after miltefosine treatment in a Nepalese patient.
Topics: Antiprotozoal Agents; Humans; Leishmaniasis, Visceral; Male; Nepal; Phosphorylcholine; Recurrence; T | 2009 |
Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient.
Topics: AIDS-Related Opportunistic Infections; HIV; HIV Infections; HIV-1; Humans; Itraconazole; Leishmanias | 2010 |
A rare case of Visceral leishmaniasis with multiple relapse and multi-drug unresponsive: successfully treated with combination therapy.
Topics: Adult; Amphotericin B; Antiprotozoal Agents; Drug Resistance, Multiple; Drug Therapy, Combination; H | 2011 |
Leishmania resistance to miltefosine associated with genetic marker.
Topics: Amphotericin B; Antiprotozoal Agents; Drug Resistance; Female; Humans; Inhibitory Concentration 50; | 2012 |
Human internal mammary artery organ culture model of coronary stenting: a novel investigation of smooth muscle cell response to drug-eluting stents.
Topics: Cell Division; Coated Materials, Biocompatible; Coronary Artery Disease; Drug Delivery Systems; Graf | 2002 |
[Leishmaniasis--oral treatment with hexadecylphosphocholine].
Topics: Administration, Oral; Adult; Antiprotozoal Agents; Child; Clinical Trials as Topic; Drug Resistance; | 2004 |
Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.
Topics: Adult; Amphotericin B; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Europe; Germany; HI | 2006 |
Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment.
Topics: Adult; Animals; Antiprotozoal Agents; Humans; Leishmania mexicana; Leishmaniasis, Cutaneous; Male; P | 2006 |
Hexadecyl-phosphorylcholine ointment for treatment of cutaneous leishmaniasis: an animal trial.
Topics: Administration, Cutaneous; Analysis of Variance; Animals; Anti-Infective Agents, Local; Antiprotozoa | 2006 |
Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses.
Topics: Adolescent; Adult; Antiprotozoal Agents; Child; Child, Preschool; Drug Resistance; Female; Humans; L | 2007 |
[Cutaneous leishmaniasis].
Topics: Animals; Biopsy; Cross-Sectional Studies; Diagnosis, Differential; Humans; Leishmania; Leishmaniasis | 2007 |
Immunoglobulin deficiencies and impaired immune response to polysaccharide antigens in adult patients with recurrent community-acquired pneumonia.
Topics: Adult; Aged; Antibodies, Bacterial; Antigens, Bacterial; Bacterial Vaccines; Community-Acquired Infe | 1997 |